Walker on Progress

Oculis Biotech, a clinical-stage biopharmaceutical company, has raised nearly $300 million to accelerate development of innovative therapies for debilitating eye diseases, including optic neuritis and dry eye disease.

Novartis’ acquisition of Avidity Biosciences signals a new era in RNA therapeutics, with a focus on delivering targeted therapies for muscular dystrophies and other genetic diseases. The deal includes a planned spin-off for cardio programs.

Cancer diagnostics firm Insight Molecular is aggressively expanding through acquisitions, fueling growth but also creating accounting complexities and short-term losses. Analysts question if the strategy will deliver long-term value.

Strong YUPELRI sales drive Theravance Biopharma's Q3 gains, but rising competition and evolving treatment options in the COPD market demand strategic adaptation.

FibroGen has restructured its operations with the sale of its China business, bolstering its cash runway and refocusing on advancing key clinical programs like FG-3246 and roxadustat. A closer look at the company's new direction.

Pharmaceutical giant Novartis expands its radioligand therapy footprint with a new California facility, aiming to meet surging demand for personalized cancer treatments. Analysis shows a rapidly growing market poised for double-digit growth.

Femasys Inc. received a significant financial boost and European regulatory approvals for its innovative, non-surgical permanent birth control device, FemBloc, potentially disrupting the contraception market.

Ernexa Therapeutics is moving forward with its novel cell therapy for platinum-resistant ovarian cancer, but faces a crowded field and financial hurdles. A deep dive into the company's progress and challenges.

Biotech firm Cadence Therapeutics seeks to redefine anticoagulation for high-risk patients, but faces a looming ‘going concern’ warning and a competitive landscape rocked by recent trial setbacks.

Voyager Therapeutics is streamlining its pipeline, prioritizing new small molecule programs alongside promising advancements in gene therapy delivery, including a novel non-viral platform and a Phase 1/2 Alzheimer's trial.

A fresh influx of funding and promising clinical data fuels 4D Molecular Therapeutics' efforts to revolutionize treatment for age-related macular degeneration, diabetic macular edema and cystic fibrosis with innovative gene therapies.

Biotech firm Protara Therapeutics is making strides with a promising cell therapy for non-muscle invasive bladder cancer and a unique treatment for a critical nutrient deficiency in patients on long-term parenteral support, bolstering its financial outlook.

Israeli medtech firm Nurami Medical receives FDA clearance for its innovative dural repair graft, ArtiFascia®, and secures significant funding, positioning it for growth in the $2 billion+ global dural repair market.

Data anomalies in a key clinical trial have sent Jasper Therapeutics’ stock plummeting and forced a dramatic refocus of its pipeline. A deep dive into the challenges and potential path forward.

Cabaletta Bio’s innovative CAR-T cell therapy for autoimmune diseases is demonstrating encouraging clinical results, but the biotech faces significant financial challenges that cast a shadow over its future.

CRISPR Therapeutics is pushing beyond its approved therapies with promising data in Alpha-1 Antitrypsin Deficiency, cardiovascular disease, and thrombosis. A closer look at the science and strategy.

Facing a critical funding crunch, Bluejay Diagnostics is pushing forward with a rapid sepsis diagnostic test, hoping to disrupt a market ripe for innovation but crowded with competition. Can they deliver before time – and money – runs out?

ADC Therapeutics has bolstered its financial position with a $60M financing, allowing it to double down on commercializing ZYNLONTA and advancing key clinical trials, despite recent revenue headwinds. The company's strategic pivot signals a focus on maximizing its lead asset.

Wave Life Sciences is making strides in metabolic and rare disease treatment with its innovative RNA-based therapies, but faces a crowded field and increasing financial scrutiny as it charts its path to commercialization.

Galecto’s acquisition of Damora Therapeutics, backed by a significant funding round, signals a promising advancement in targeted therapies for Myeloproliferative Neoplasms driven by the CALR mutation. The deal highlights a novel biotech launchpad model.